ACCEL Lite: From JACC: Abbreviated Antiplatelet Therapy after Coronary Stenting in Patients with Myocardial Infarction at High Bleeding Risk

<p>This subgroup analysis from the MASTER-DAPT trial demonstrates that in high-bleeding risk patients with acute or recent myocardial infarction it is safe to stop DAPT 1 month after stenting and that this strategy provides a reduction in bleeding risk.</p> <p>In this interview, Pieter C. Smits MD, PhD, FESC and Sidney C. Smith Jr. MD, MACC, with Jeffrey Hsu MD, PhD, discuss a recent piece from <em>JACC</em>: Abbreviated Antiplatelet Therapy after Coronary Stenting in Patients with Myocardial Infarction at High Bleeding Risk.</p> <p> </p> <p><a href= "https://itunes.apple.com/us/podcast/eagles-eye-view-your-weekly-cv-update-from-acc-org/id1274635046"> Subscribe on Apple</a> Podcasts | <a href= "https://play.google.com/music/listen#/ps/I6dtkumvaipematzgzmbph2koiq"> Subscribe on Google Play</a> | <a href= "http://www.acc.org/education-and-meetings/products-and-resources/accel-audio"> Subscribe to ACCEL</a></p>